Effect of injected medroxyprogesterone acetate on myometrial invasion in preoperative endometrial cancer: A randomized control trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190728003

Enrollment

120

Registered

2019-07-28

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

Injected medroxyprogesterone acetate 150 mg intramuscular every 12 weeks,Saline solution 150 mg intramuscular every 12 weeks

Experimental Drug,Experimental Other

Injected medroxyprogesterone acetate,injected placebo

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: - Endometrial cancer patient - Waiting for surgery more than 4 weeks

Exclusion criteria

Exclusion criteria: 1.History of medroxyprogesterone acetate allergy 2.Evidence of extrauterine cancer 3.history of breast cancer 4.hepatic disease 5.defined as persistent systolic blood pressure > 170 mmHg or diastolic blood pressure > 110 mmHg 6.osteoporosia, anorexia nervosa, rheumatoid arthritis, chronic glucocorticoid use 7. Using other progesterone drugs such as contraceptive drugs, injected or IUDs within 6 weeks before diagnosed of endometrial cancer 8. Venous thromboembolism;VTE 9. breast mass by physical examination or abnormal mammogram

Design outcomes

Primary

Measure	Time frame
Myometrial invasion after surgery From the pathological report	—

Secondary

Measure	Time frame
Cervical stromal invasion after surgery From the pathological report	—

Countries

Thailand

Contacts

Public ContactAmornrat Temtanakitpaisan

Khon Kaen university

kunglekmed@hotmail.com+66-850033833

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026